Mycophenolate mofetil for myasthenia gravis: a clear and present controversy
Chad Heatwole, Emma CiafaloniDepartment of Neurology, The University of Rochester, Rochester, New York, USAAbstract: Mycophenolate mofetil (MMF) has been used to treat myasthenia gravis (MG) for over 10 years. MMF’s use in the MG population stems from its theoretical mechanism of actio...
Enregistré dans:
| Auteurs principaux: | , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Dove Medical Press
2008
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/8c86069ab9fb4db2873d6c827b7de2e2 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
| Résumé: | Chad Heatwole, Emma CiafaloniDepartment of Neurology, The University of Rochester, Rochester, New York, USAAbstract: Mycophenolate mofetil (MMF) has been used to treat myasthenia gravis (MG) for over 10 years. MMF’s use in the MG population stems from its theoretical mechanism of action and the medical literature that supports its benefit in MG patients. Recently, two large, double-blinded, placebo-controlled, randomized clinical trials were initiated to study the effectiveness of MMF for MG. One of these studies found no benefit in taking MMF with 20 mg of prednisone as compared to taking prednisone alone, while the other study demonstrated no advantage in taking MMF against placebo during a 36-week prednisone taper. This article critically reviews the medical literature on MMF’s use in MG and suggests further research avenues on this topic.Keywords: myasthenia gravis, mycophenolate mofetil, CellCept |
|---|